Aakash Desai Highlights New Study on BRAF-Mutated NSCLC: Personalization Over One-Size-Fits-All
Aakash Desai, Assistant Professor and Associate Director of Phase 1 and Precision Oncology Program at the UAB O’Neal Comprehensive Cancer Center, shared a post on X about recent article Marcel Wiesweg and colleagues authored:
“In JTO and JTO CRR BRAF-mutated NSCLC.
1L targeted therapy (dabrafenib/trametinib) vs. chemo-IO shows:
– Similar OS outcomes
– PD-L1 status and gender influence prognosisPersonalization > one-size-fits-all”
Title: Treatment sequences in BRAF-V600-mutated non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy
Journal: Journal of Thoracic Oncology
Authors: Marcel Wiesweg, Ali Alaffas, Anna Rasokat, Felix Carl Saalfeld, Maximilian Rost, Christin Assmann, Franziska Herster, Moritz Hilbrandt, Frank Griesinger, Anna Kron, Julia Roeper, Franziska Glanemann, Cornelia Kropf-Sanchen, Martin Reck, Jonas Kulhavy, Albrecht Stenzinger, Jürgen Wolf, Martin Sebastian, Martin Schuler, Martin Wermke, Nikolaj Frost, Hans-Georg Kopp, Petros Christopoulos, Matthias Scheffler
Read Full Article.
More posts featuring Aakash Desai on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023